BirchBioMed is a clinical stage pharmaceutical company focused on developing treatments for scarring (fibrosis) and related skin disorders, certain autoimmune diseases, and for organ fibrosis. We hold the exclusive, worldwide, pharmaceutical licenses from the University of British Columbia (“UBC”) for two scientific technologies, FS1/FS2 and AI-001.

Based on early pre-clinical and clinical studies we have conducted to date, we believe they may potentially represent future medical breakthroughs in the treatment of certain debilitating conditions/disorders in need of novel, better solutions.

POSITIVE TOPLINE DATA FROM PHASE 2 STUDY OF FS2
FOR TREATMENT OF KELOID SCARS